Introduction
The Selecting Therapeutic Targets in Inflammatory Bowel Disease II (STRIDE-II) initiative provides therapeutic targets for inflammatory bowel disease (IBD) within a treat-to-target framework. However, whether and how these are used and reached in daily practice is unknown. The objective of this study was to investigate the treatment response of Crohn’s disease (CD) patients and compliance to the STRIDE-II recommendations in clinical practice.
Aims & Methods
CD patients enrolled in a remote monitoring care-path via myIBDcoach at a university and a large non-academic hospital, starting a new pharmacological advanced therapy between January 1st 2020 and December 31st 2024 were eligible for inclusion. The short-term treatment target was clinical response defined as ≥50% reduction in the two-item Patient-Reported Outcome (PRO2) or the Monitor IBD at Home (MIAH) questionnaire.1 Intermediate targets were clinical remission based on PRO2 or MIAH and normalisation of inflammatory parameters, i.e. faecal calprotectin and CRP. Long-term targets were the absence of disability based on IBD-control, restoration of quality of life based on PROMIS-QoL or EQ-VAS, and endoscopic remission based on Simple Endoscopic Score for CD (SES-CD). If ileocolonoscopy data were not available, a combination of patient-reported outcome measures and calprotectin was used as a surrogate marker. The assessment and achievement of targets within predefined timeframes as well as time to achieve the treatment targets irrespective of timeframes were evaluated.
Results
A total of 374 cases were included in the analysis. Among these, 44.9% initiated anti-TNF therapy, 25.7% Ustekinumab, 16.0% Vedolizumab, and 13.4% other advanced therapies, including JAK inhibitors and IL-23 antagonists. Achievement of short-, intermediate-, and long-term treatment targets showed substantial variation depending on the outcome definition used. The overall rates of target attainment remained low (Table 1). In addition, during the total follow-up, 229 cases achieved zero targets, 78 cases achieved 1 target, 48 cases achieved 2 targets, 16 cases achieved 3 targets, 3 cases achieved 4 targets and zero cases achieved 5 or more targets.
Table 1: Achievement of treatment targets according to STRIDE-II recommendations (based on measured data per time point)
Short-term targets Medication | Clinical response: PRO2 ≥50% reduction, n (%) | Clinical response: MIAH ≥50% reduction, n (%) | |
Anti-TNF (within 4 weeks)*
Vedolizumab (within 11 weeks)*
Ustekinumab (within 7 weeks)*
Other (within 7 weeks) Total | 2/9 (22.2)
3/12 (25.0)
3/8 (37.5)
0/2 (0.0)
8/31 (25.8) | 0/9 (0.0)
4/12 (33.3)
0/8 (0.0)
0/2 (0.0)
4/31 (12.9) |
Intermediate-term targets Medication | Clinical remission (PRO2 <8), n (%) | Clinical remission (MIAH ≤3.6), n (%) | CRP <10 mg/L n (%) | FCP <150 µg/g n (%) | |
Anti-TNF (4-11 weeks)*
Vedolizumab (15-17 weeks)*
Ustekinumab (11-14 weeks)*
Other (11-14 weeks)* Total | 6/21 (28.6)
3/23 (13.0)
9/23 (39.1)
3/5 (60.0)
21/72 (29.2) | 13/21 (61.9)
11/23 (47.8)
13/23 (56.5)
3/5 (60.0)
40/72 (55.6) | 27/31 (87.1)
11/16 (68.8)
14/17 (82.4)
10/14 (71.4)
62/78 (79.5) | 16/20 (80.0)
5/14 (35.7)
6/11 (54.5)
7/15 (46.7)
35/60 (58.3) |
Long-term targets Medication | Clinical remission (PRO2 <8), n (%) | Clinical remission (MIAH ≤3.6), n (%) | No disability (IBD control ≥13), n (%) | QoL (PROMIS-QoL ≥ good), n (%) | QoL (EQ-VAS ≥65), n (%) | Combined remission (PRO2 <8 and FCP <150 ug/g), n (%) | Combined remission (MIAH ≤3.6 and FCP <150 ug/g), n (%) | Endoscopic healing (SES-CD <3), n (%) |
Anti-TNF (within 17 weeks)*
Vedolizumab (within 24 weeks)*
Ustekinumab (within 19 weeks)*
Other (within 19 weeks)* Total | 19/57 (33.3)
1/7 (14.3)
2/16 (12.5)
0/3 (0)
22/83 (26.5) | 36/57 (63.2)
3/7 (42.9)
10/16 (62.5)
1/3 (33.3)
50/83 (60.2) | 34/57 (59.6)
1/7 (14.3)
4/16 (25.0)
0/3 (0)
39/83 (47.0) | 7/12 (58.3)
0/0 (0)
1/3 (33.3)
0/1 (0)
8/16 (50.0) | 9/13 (69.2)
0/0 (0)
0/2 (0)
1/1 (100)
10/16 (62.5) | 5/16 (31.3)
1/2 (50.0)
0/7 (0)
0/1 (0)
6/26 (23.1) | 7/16 (43.8)
1/2 (50.0)
2/7 (28.6)
0/1 (0)
10/26 (38.5) | 2/5 (40.0)
1/1 (100.0)
1/1 (100.0)
1/1 (100.0)
5/8 (62.5) |
Abbreviations: n, number of cases; PRO2, two-item patient reported outcome; MIAH, Monitor IBD at Home; CRP, C-reactive protein; FCP, faecal calprotectin; QoL, Quality of life; EQ-VAS, EuroQoL visual analogue scale; SES-CD, Simple Endoscopic Score for Crohn's Disease
*Time (mean number of weeks) required for achieving the treatment target after starting treatment according to STRIDE-II
Conclusion
In this real-world cohort of patients with CD starting a new advanced therapy, evaluation and achievement of STRIDE-II treatment targets was generally low in the proposed timeframes. This suggests that these recommendations may be challenging to assess routinely and attain in clinical practice. Although STRIDE-II provides an important therapeutic framework, further refinement of future recommendations is warranted to align with daily practice.
References
1: de Jong MJ, Roosen D, Degens JHRJ, van den Heuvel TRA, Romberg-Camps M, Hameeteman W, Bodelier AGL, Romanko I, Lukas M, Winkens B, Markus T, Masclee AAM, van Tubergen A, Jonkers DMAE, Pierik MJ. Development and Validation of a Patient-reported Score to Screen for Mucosal Inflammation in Inflammatory Bowel Disease. J Crohns Colitis. 2019 Apr 26;13(5):555-563. doi: 10.1093/ecco-jcc/jjy196. PMID: 30476099.